Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. | Front Oncol | 2021 | 33937038 | PubTator, text mining | PubMed |
| Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease "sanctuary" during venetoclax treatment? | Clin Case Rep | 2021 | 33936674 | PubTator, text mining | PubMed |
| Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. | Leukemia | 2021 | 33935280 | PubTator, text mining | PubMed |
| Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response. | EMBO J | 2021 | 33934394 | PubTator, text mining | PubMed |
| Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. | J Immunother Cancer | 2021 | 33931471 | PubTator, text mining | PubMed |
| Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis. | BMC Cancer | 2021 | 33931030 | PubTator, text mining | PubMed |
| LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2021 | 33925565 | PubTator, text mining | PubMed |
| Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges. | Cancers (Basel) | 2021 | 33921029 | PubTator, text mining | PubMed |
| From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. | Cancers (Basel) | 2021 | 33917885 | PubTator, text mining | PubMed |
| Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. | Hemasphere | 2021 | 33912812 | PubTator, text mining | PubMed |
| SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease? | J Exp Med | 2021 | 33904890 | PubTator, text mining | PubMed |
| Current and future treatment strategies in chronic lymphocytic leukemia. | J Hematol Oncol | 2021 | 33902665 | PubTator, text mining | PubMed |
| Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. | Front Cell Dev Biol | 2021 | 33898440 | PubTator, text mining | PubMed |
| A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. | Cell Host Microbe | 2021 | 33894127 | PubTator, text mining | PubMed |
| Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review. | J Blood Med | 2021 | 33880072 | PubTator, text mining | PubMed |
| Single-cell multi-omics analysis of the immune response in COVID-19. | Nat Med | 2021 | 33879890 | PubTator, text mining | PubMed |
| Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. | Mol Cell | 2021 | 33878293 | PubTator, text mining | PubMed |
| Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. | Blood | 2021 | 33861303 | PubTator, text mining | PubMed |
| Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. | Elife | 2021 | 33843586 | PubTator, text mining | PubMed |
| Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia. | Leukemia | 2021 | 33833385 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=47